Operator
Good morning, ladies and gentlemen, and welcome to the NeoGenomics First Quarter 2021 Earnings Call. [Operator Instructions]
It is now my pleasure to turn the floor over to your host, Doug Vianor. Sir, the floor is yours.
Douglas M. VanOort
Chairman of the Board of Directors and Executive Chairman
Well, thank you, Holly, and good morning, everyone. I d like to welcome everyone to NeoGenomics First Quarter 2021 Conference Call. We have a lot of exciting news to share today. But first, let me introduce my fellow team members on the call. Joining me this morning from our Fort Myers headquarters are Mark Mallon, our new Chief Executive Officer; Kathryn McKenzie, our Chief Financial Officer; George Cardoza, President of our Pharma Services Division; Bill Bonello, President of our Informatics Division; Doug Brown, our Chief Strategy and Corporate Development Officer; and Charlie Edson, our Manager of Investor Relations. Also joining us this morning via phone from the Unite
NeoGenomics to Acquire Inivata - Combining Best-In-Class Liquid Biopsy Technology with Leading Community Oncology Platform streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
First-Quarter 2021 Results and Highlights: Consolidated revenue increased 9% to $116 million Clinical Services revenue increased 4% to $96 million Pharma Services revenue increased 46% to $19 million Completed
NeoGenomics Reports 9% Revenue Growth to $116 Million in the First Quarter
ACCESSWIRE
First-Quarter 2021 Results and Highlights:
Consolidated revenue increased 9% to $116 million
Clinical Services revenue increased 4% to $96 million
Pharma Services revenue increased 46% to $19 million
Completed the acquisition of Trapelo Health in April
FORT MYERS, FL / ACCESSWIRE / May 5, 2021 / NeoGenomics, Inc. (NASDAQ:NEO) (the
Company
), a leading provider of cancer-focused genetics testing services, today announced its first-quarter results for the period ended March 31, 2021.
Mark W. Mallon, the Company s CEO said I couldn t be more excited to be joining NeoGenomics at such a pivotal time in the Company s history. Trends in the business are strong and we are positioned well to take market share as we emerge from the pandemic. Today s announced acquisition of Inivata along with the completion of the acquisition of Trapelo Health in April are significant milestones on our journey t